INTRODUCTION
Juvenile idiopathic arthritis (JIA) is a heterogeneous group of conditions which encompasses all forms of arthritis of unknown etiology lasting for at least 6 weeks and with onset before the age of 16 years [1] . As a result of the lack of pathognomonic features, the diagnosis of JIA is one of exclusion among all possible causes of chronic arthritis in childhood.
The aim of this review is to provide a summary of the epidemiology, clinical features, diagnosis, and treatment of JIA. This article was based on previously conducted studies and did not involve any new studies of human or animal subjects performed by any of the authors.
EPIDEMIOLOGY
JIA is the most common chronic rheumatic disease of childhood and a leading cause of short-and long-term disability. Its reported incidence and prevalence in European and
North American populations range from 2 to 20 and from 16 to 150 per 100,000, respectively [1] . However, remarkable disparity in the frequency of JIA subtypes has been noticed in different geographical areas or ethnic groups. In Western countries oligoarthritis is the most common subtype, while polyarthritis predominates in Costa Rica, India, New Zealand, and South Africa [2, 3] . In Asia, systemic arthritis accounts for a greater proportion of childhood arthritis [2, 4] . In India, Mexico, and Canada, a greater incidence of enthesitis-related arthritis (ERA) has been registered, reflecting, at least in part, the high frequency of the human leukocyte antigen (HLA)-B27 in these populations [2] . Rheumatoid factor (RF)-positive polyarthritis is the less common subtype. Distinct distributions of age at onset and sex characterize each onset type. Broader insights into the worldwide variability of JIA phenotypes will come out of the multinational study of the EPidemiology, treatment and Outcome of Childhood Arthritis (EPOCA Study [5] ), which has enrolled thus far around 9000 patients from 42 countries in five continents. The potential role of phenotypic variability of JIA across races or ethnic groups in explaining genetic predisposition and pathogenesis has been recently discussed [6] .
CLASSIFICATION
Over the last few decades, several classification systems for chronic arthritis in childhood have been proposed [7] . The current scheme, based on the criteria created by the Pediatric Task
Force of the International League of Associations for Rheumatology (ILAR) [8] ,
introduced the unifying term of JIA and outlined seven disease categories (Table 1 ) [7] , on the basis of the clinical and laboratory features present in the first 6 months of illness [9] . Although the ILAR classification has served well to harmonize the terminology across Europe and North America and the criteria used to enroll patients in research studies and clinical trials, it has recently been subject to several criticisms [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . In particular, some concerns have been raised about the use of the number of affected joints and the presence of psoriasis as parameters to define homogeneous disease entities [17] . Furthermore, it has been shown that the presence of antinuclear antibodies (ANA) identifies a homogeneous disease subset across various ILAR categories 
CLINICAL MANIFESTATIONS
Systemic arthritis accounts for 5-15% of children with JIA in North America and Europe [21] . The ILAR criteria for systemic arthritis require the presence of arthritis accompanied or preceded by a documented quotidian fever of at least 2 weeks' duration, plus at least one of the following: characteristic rash ( Fig. 1) , generalized symmetrical lymphadenopathy, enlargement of liver or spleen, or serositis (pericarditis, pleural or pericardial effusion, rarely peritonitis). The fever has a typical intermittent pattern, with one or two daily spikes, up to 39°C or higher, followed by rapid return to baseline. The erythematous, salmon pink, evanescent macular rash usually appears with fever [2] .
Arthritis is often symmetrical and polyarticular, but may be absent at onset and develop much later. In these cases, diagnosis cannot be considered definite until arthritis is present. Enthesitis-related arthritis (ERA) mainly affects male patients older than 6 years and is characterized by the association of enthesitis and arthritis [2, 3] . Most of the patients are HLA-B27 positive and have negative RF and ANA. The onset of ERA may be insidious, as intermittent osteoarticular pain and stiffness may be present, with or without objective inflammation of peripheral joints. The presence of enthesitis, especially at the calcaneal insertions of the Achilles tendon, the plantar fascia, and the tarsal area, is the most helpful diagnostic feature. The joints of the lower extremities and the hip are predominantly affected. Sacroiliitis, mono-or bilateral, may be a clinical feature of ERA, as a part of the axial skeleton involvement. A plain 
DIAGNOSIS
Juvenile idiopathic arthritis (JIA) is a diagnosis of exclusion that, when suspected, requires a complete clinical evaluation, including family to personal history and recent pathologic events, and specific attention to pain and morning stiffness. A detailed physical examination should always be performed to examine all body joints at both first evaluation and follow-up visits [33] . At the end of the visit, the physician is asked to provide his/her global rating of the overall level of disease activity on a visual analog scale (VAS), ranging from 0 (no activity) to 10 (maximum activity) [33, 34] . The differential diagnosis of JIA is wide ( Table 3 ). The identification of systemic JIA may be challenging as arthritis is often not present at onset. endopeptidase that may directly damage cartilage and bone, were shown to be higher in children with ERA than in healthy subjects 
Treatment
The optimal approach to the management of a child with JIA is based on a multidisciplinary team comprising a pediatric rheumatologist, ophthalmologist, orthopedic surgeon, specialist nurse, physical therapist, occupational therapist, and psychologist [2] . Non-pharmacological and pharmacological interventions may aid in the management of JIA patients. [114] , growth velocity and bone status [115, 116] and reduce the progression of radiographic joint damage [117] . Complete disease quiescence can be achieved in half of the patients [118, 119] .
Non-Pharmacological Interventions
Infliximab, a chimeric TNF-a inhibitor, failed to show a statistically significant difference in its primary outcome at 3 months in a placebo-controlled trial [120] . However, after 1 year the response to infliximab was comparable to that observed with etanercept.
Paradoxically, despite similar efficacy, patients treated with 3 mg/kg of infliximab experienced a greater frequency of serious adverse events and autoantibodies than those given 6 mg/kg.
Infliximab is not approved for use in JIA. 
SAFETY OF BIOLOGICS
Most data on the safety of etanercept come from a drug-specific registry [112] and several national registries [113, 148, 149] . In the 594 patients included in the drug-specific registry, the rates of adverse events (AEs), serious adverse events (SAEs), medically important infections, and autoimmune events were similar in those treated with MTX alone, etanercept alone, and MTX and etanercept in combination [112] . No malignancies, TB, opportunistic infections or demyelinating diseases, new autoimmune diseases, or deaths were reported [121] .
Twenty-six SAEs, including six serious infections, were observed in a randomized controlled trial of infliximab [120] . The greater frequency of SAEs, infusion reactions, antibodies to infliximab, and newly produced ANA and anti-DNA antibodies in patients treated with 3 mg/kg rather than in those who were given 6 mg/kg has been discussed above.
In clinical practice, it is important to consider that the administration of anti-TNF agents has been associated with an increasing risk of TB infection onset or reactivation. For this reason, an accurate screening for TB during baseline assessment and a careful monitoring for the entire duration of treatment are mandatory [151] .
The potential of anti-TNF agents to induce malignancy is still uncertain. In 2010, the US FDA reported 48 malignancies in pediatric patients who had been treated with TNF inhibitors [152] . However, only 19 of the 48 cases had chronic arthritis and the study was affected by a number of confounding biases, which hampered the interpretation of its findings [153] . The subsequent studies suggested that JIA itself is associated with an increased risk of malignancy and that treatment with TNF blockers does not augment this risk [154] [155] [156] [157] . A more definite answer to these safety concerns will be provided by a large-scale effort aimed at collecting safety data related to biologic agents in a multinational population of children with JIA, which is underway.
SAEs reported for other biologics mostly include serious non-opportunistic infections for abatacept, and reaction in the injection site and cases of hepatitis [158] for anakinra.
The tolerability profile of tocilizumab has been studied in different trials over the last few years, but a pivotal role is to attribute to the TENDER and CHERISH studies for systemic JIA and polyarticular JIA, respectively [133, 146] . 
